Literature DB >> 1325212

Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.

D Benjamin1, T J Knobloch, M A Dayton.   

Abstract

A recent addition to the lymphokine network is human IL-10 (hIL-10). This novel lymphokine has striking homology to BCRF1 protein, the product of a previously uncharacterized open-reading frame in the Epstein-Barr virus (EBV) genome. To date, IL-10 expression has been described in several T clones induced with anti-CD3 and phorbol myristate acetate (PMA), in monocytes stimulated with lipopolysaccharide (LPS), and in murine B-cell lymphomas. We sought to determine whether human B cells express hIL-10 and, if so, its relationship to EBV and to other B-cell lymphokines. We studied 21 EBV-positive B-cell lines derived from patients with acquired immunodeficiency syndrome (AIDS) and Burkitt's lymphoma (n = 6), American Burkitt's (n = 3), African Burkitt's (n = 5), and normal lymphoblastoid cell lines (n = 7), in comparison with seven EBV-negative cell lines. All cell lines were activated with the tumor promoters PMA and teleocidin and were studied by Northern blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), and enzyme-linked immunoadsorbent assay (ELISA). We demonstrated that EBV-positive cell lines derived from patients with American Burkitt's lymphoma, and especially those from patients with AIDS, constitutively express large quantities of hIL-10 by Northern blot analysis and ELISA (range, 3,101 to 25,915 pg/mL), and that both teleocidin and PMA induce hIL-10 in these cell lines. In contrast, six of seven EBV-negative cell lines did not express hIL-10 even by RT-PCR, and hIL-10 was not triggered by PMA or teleocidin. To assure that the 350 bp amplified by PCR was hIL-10 and not BCRF1, we used PCR primers, which do not amplify a fragment from plasmid templates containing BCRF1. Cloning and sequencing of the 350 bp product also demonstrated that B-cell IL-10 is identical to hIL-10 from the T-cell clone B21. Correlation of hIL-10 with other B-cell lymphokines secreted by these B-cell lines demonstrated that hIL-10 secretor cell lines also constitutively secrete or can be induced to secrete IL-6, although to a much lesser amount. Since both lymphokines influence B-cell growth and differentiation, we suggest that hIL-10 may contribute to the polyclonal B-cell activation and hyperglobulinemia seen in AIDS patients. Finally, several reports support the hypothesis that EBV is an important cofactor in the development of human immunodeficiency virus type 1 (HIV-1)-related B-cell lymphomas. Detection of large quantities of hIL-10 in B-cell lines derived from AIDS patients, the close association between EBV and hIL-10 shown in this report, and the ability of BCRF1 to capture hIL-10 activities, make hIL-10/BCRF1 an attractive candidate as a factor causing B-cell growth and immortalization in patients with AIDS and B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325212

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy.

Authors:  E Stylianou; P Aukrust; D Kvale; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

Review 3.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

Review 4.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL.

Authors:  S Ramachandra; R A Metcalf; T Fredrickson; G E Marti; E Raveche
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

6.  Production of interleukin-10 by human bronchogenic carcinoma.

Authors:  D R Smith; S L Kunkel; M D Burdick; C A Wilke; M B Orringer; R I Whyte; R M Strieter
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

Review 7.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 8.  HIV-mediated B-lymphocyte activation and lymphomagenesis.

Authors:  J G Monroe; L E Silberstein
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

Review 9.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity.

Authors:  G Gaidano; C Pastore; C Lanza; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

10.  Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas.

Authors:  M L Boulland; V Meignin; K Leroy-Viard; C Copie-Bergman; J Brière; R Touitou; P Kanavaros; P Gaulard
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.